Compare the files
Lazarus Research Peptides: compare the recoveries
Activity in an assay, mechanics in a mouse lung, a patient's blood-cell count and survival each answer a different question.
What returned in each experiment?
The most revealing comparison starts with the thing that recovered. I resist giving these peptides a single score: a zinc-dependent assay and an intensive-care mortality endpoint have so little in common that a league table would mislead.
| File | Reported outcome | Experimental setting | Condition attached to the finding |
|---|---|---|---|
| Thymulin and zinc | Activity corrected with zinc supplementation | Animal and human zinc-deficiency observations summarized in a review | Activity requires the zinc-bound complex |
| Thymulin gene delivery | Normalized inflammation, fibrosis and lung mechanics at 20 days | Established allergic asthma in mice | Plasmids carried in mucus-penetrating nanoparticles |
| Thymosin alpha-1 | Higher T-cell numbers and reduced exhaustion markers | Retrospective severe COVID-19 cohort | Association in patient records, with potential confounding |
| Thymosin alpha-1 | No significant 28-day mortality benefit | TESTS randomized sepsis trial | The clinical endpoint remained negative |
| KPV | Earlier recovery and reduced colonic inflammation | Mouse colitis models | No published human clinical trials |
Molecule, partner and carrier
Thymulin has nine amino acids and a required zinc partner. Thymosin alpha-1 has 28 amino acids and a human clinical record. KPV has three amino acids and a persistent delivery problem. Their names supply no reason to treat them as interchangeable.
The carrier changes the claim in practical ways. Thymulin-expressing genetic material in a mouse airway, an active analog expressed from a vector in athymic mice, and free peptide are different interventions. Likewise, the KPV hydrogel formulation and the KPV/FK506 combination deserve the credit assigned to those particular experiments. I become less persuaded whenever a retelling drops the carrier or the combination partner.
Human evidence and U.S. status
The thymosin alpha-1 clinical review reports thymalfasin approval in more than 35 countries. It is not FDA-approved for marketing in the United States. Thymulin has no FDA-approved indication; KPV is also unapproved and lacks published human clinical trials. The thymulin literature is predominantly preclinical, with sparse, older human work that includes analogs. Neither Thymulin nor KPV is specifically named on the WADA Prohibited List, but as unapproved peptides they should be treated cautiously in any sport or competitive context.
Compounded prescription care requires a licensed provider's review and decision. Not every request leads to a prescription; availability varies by state and treatment. Compounded medications are not FDA-approved.
I trust a recovery claim most when it names the exact function that returned. That leaves the zinc finding unusually clear, the mouse delivery experiments inventive, and the human sepsis survival claim constrained by TESTS. None supplies a treatment plan for an individual reader.